Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2001
10/25/2001WO2001078681A1 Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
10/25/2001WO2001078680A2 Pharmaceutical compositions comprising fluvastatin
10/25/2001WO2001078677A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials
10/25/2001WO2001078675A1 Use of natural substances in the production of cosmetic preparations
10/25/2001WO2001078660A2 Topical micronutrient delivery system and uses thereof
10/25/2001WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078580A2 A method combining inducing hypothermia and administering a therapeutic agent
10/25/2001WO2001078533A2 Nutritional modules
10/25/2001WO2001078532A1 Composition comprising free amino acids
10/25/2001WO2001078531A2 Conjugated linoleic acid powder
10/25/2001WO2001078530A2 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
10/25/2001WO2001078529A2 Compositions and methods for improving vascular health
10/25/2001WO2001078511A1 Active substance combinations with insecticidal and acaricidal properties
10/25/2001WO2001049317A9 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
10/25/2001WO2001049288A9 Novel compounds and compositions as protease inhibitors
10/25/2001WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001WO2001041778B1 Melanin synthesis inhibition compound and composition containing the same
10/25/2001WO2001038584A3 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
10/25/2001WO2001034546A3 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
10/25/2001WO2001034172A3 Methods and compositions for treating reward deficiency syndrome
10/25/2001WO2001028987A8 Benzylcycloalkyl amines as modulators of chemokine receptor activity
10/25/2001WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001WO2001027099A3 Bicyclic compounds composition and method for stabilizing the same
10/25/2001WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001WO2001022976A3 Combination of a statin and ex-vivo treated blood for treating artheroclerosis
10/25/2001WO2001022950A3 Diosolane nucleoside analogs for the treatment or prevention of viral infection
10/25/2001WO2001021762A3 Method of decreasing cholesterol uptake
10/25/2001WO2001021605A3 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
10/25/2001WO2001021220A3 Bioprosthetic heart valves
10/25/2001WO2001021154A3 Surface modified particulate compositions of biologically active substances
10/25/2001WO2001019798A3 Inhibitors of factor xa
10/25/2001WO2001012663A3 Hematopoietic regulatory factors and methods of use thereof
10/25/2001WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
10/25/2001WO2000064896A9 Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
10/25/2001WO2000061541A8 Pharmaceutical compounds
10/25/2001WO2000056737A9 Calanolides for inhibiting btk
10/25/2001WO2000056724A9 Oxazole and thiazole combinatorial libraries
10/25/2001WO2000054768A9 Anti-first-pass effect compounds
10/25/2001WO2000054761A9 Regulation of phospholipase d activity
10/25/2001WO2000048554A9 Synergistic antimicrobial skin washing compositions
10/25/2001WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001WO2000040605A9 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/25/2001US20010034452 Epothilons C and D, preparation and compositions
10/25/2001US20010034451 Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders
10/25/2001US20010034448 New compounds, their preparation and use
10/25/2001US20010034447 N-(5-tert-butyl-2-methoxyphenyl)-n'-(4-(1-oxoisoindolin-5-ylox y)penyl)urea as anticarcinogenic agents
10/25/2001US20010034444 Treating schizophrenia, depression, and Parkinson's disease; side effect reduction
10/25/2001US20010034440 Complexing the target cell with therapeutic agent; antiproliferative agent
10/25/2001US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus
10/25/2001US20010034374 Core formulation
10/25/2001US20010034373 Low dose modafinil for enhancement of cognitive function
10/25/2001US20010034372 Treatment of fibromyalgia with ubiquinone 10 and succinic acid
10/25/2001US20010034371 Antidiabetic agents
10/25/2001US20010034370 Carnosic acid derivatives for promoting synthesis of nerve growth factor
10/25/2001US20010034367 Compositions and methods for the treatment of cystic fibrosis
10/25/2001US20010034365 Anticonvulsants, antiepilepsy
10/25/2001US20010034364 Isoprenoid pathway inhibitors for stimulating bone growth
10/25/2001US20010034363 Water soluble paclitaxel derivatives
10/25/2001US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001US20010034361 Amide derivatives for antiangiogenic and/or antitumorigenic use
10/25/2001US20010034360 Medicament
10/25/2001US20010034359 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
10/25/2001US20010034358 Human immunodeficiency syndrone, hepatitis virus
10/25/2001US20010034357 Substituted pyridine compounds useful for controlling chemical synaptic transmission
10/25/2001US20010034356 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
10/25/2001US20010034355 Treatment of ocular hypertension
10/25/2001US20010034354 Antiulcer agents
10/25/2001US20010034353 Administering a mixture of antibiotic, nonsteroid antiinflammatory drug and a quinolone compound
10/25/2001US20010034352 Cardiovascular disorders
10/25/2001US20010034351 A quinazoline compound
10/25/2001US20010034349 Methods of hydrating mucosal surfaces
10/25/2001US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001US20010034347 A pyrido(1,2-a)pyrazine compound
10/25/2001US20010034345 Administering a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
10/25/2001US20010034344 Use of known agonists of the central cannabinoid receptor CB1
10/25/2001US20010034342 Brain disorders, antiischeic agents
10/25/2001US20010034341 Bactericides
10/25/2001US20010034340 Hormone replacement therapy
10/25/2001US20010034339 For eyes, ears or noses
10/25/2001US20010034338 Administering synergistic mixture of phytosterol and policosanol
10/25/2001US20010034337 Antiproliferative agents
10/25/2001US20010034335 Sulfated polysaccharide
10/25/2001US20010034330 Administering a mixture containing dinucleotide
10/25/2001US20010034329 Nucleic acids
10/25/2001US20010034328 Treatment of male chronic pelvic pain syndrome
10/25/2001US20010034321 Salts with polycations such as chitosan; treatment of skin disorders
10/25/2001US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001US20010034038 Isolated ductal fluid sample
10/25/2001US20010033881 Composition of fructose, vitamin b complex and taurine; effectively and rapidly controlling the effects of excessive alcohol consumption
10/25/2001US20010033873 An aqueous emulsion of fennel oil
10/25/2001US20010033872 Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and St. John's Wort for the treatment of mental disturbances
10/25/2001US20010033870 A combination of an estrogen and progestin for female hormoe replacement therapy, to provide contraception; minimizes skin damage, irritation or sensitization
10/25/2001US20010033867 Systems and methods for local delivery of an agent
10/25/2001US20010033866 Sustained release oral formulations
10/25/2001US20010033865 Melt-extrusion multiparticulates
10/25/2001US20010033864 Low dose entecavir formulation and use
10/25/2001US20010033859 Transdermal therapeutic system for delivery of dofetilide
10/25/2001US20010033858 Sustained release
10/25/2001US20010033854 Chelate compound
10/25/2001US20010033848 Adjustment of cellular nicotinamide-adenine dinucleotide